A Single-Dose, Open-Label, Randomized, Parallel-Group Study to Assess the Relative Bioavailability of 7 Test Tablet Formulations of JNJ-56021927 With Respect to the Capsule Formulation of JNJ-56021927 Under Fasted Conditions in Healthy Male Subjects

Trial Profile

A Single-Dose, Open-Label, Randomized, Parallel-Group Study to Assess the Relative Bioavailability of 7 Test Tablet Formulations of JNJ-56021927 With Respect to the Capsule Formulation of JNJ-56021927 Under Fasted Conditions in Healthy Male Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 25 Oct 2016

At a glance

  • Drugs Apalutamide (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Aragon Pharmaceuticals; Janssen Research & Development
  • Most Recent Events

    • 26 May 2014 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
    • 15 Jan 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top